Drawing for APPLIED CLINICAL CONCEPTS

USPTO serial 75546928

APPLIED CLINICAL CONCEPTS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CAPSHAW, DANIEL
Law office
FILE REPOSITORY (FRANCONIA)

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with APPLIED CLINICAL CONCEPTS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Susan Freya Olive

SUSAN FREYA OLIVE OLIVE & OLIVE PAPOST OFFICE BOX 2049DURHAM, NC 27702UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
039providing drug distribution services, namely, shipment and tracking of pharmaceutic products throughout the worldACTIVE—
042providing pharmacy services; developing drug protocols and study materials for clinical trials in the pharmacy field; providing drug tracking and drug accountability data; providing drug usage and drug requirement projection reports for clinical trials; and, providing consultation services in the fields of pharmaceutics and of domestic and foreign regulatory proceduresACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ABN2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Dec 15, 2000ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 10, 2000CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 9, 2000DOCKASSIGNED TO EXAMINER—
Dec 6, 1999ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Dec 2, 1999PETRPETITION TO REVIVE-RECEIVED—
Nov 26, 1999PETGPETITION TO REVIVE-GRANTED—
Mar 22, 1999CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 8, 1999DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance